A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

NCT05138159 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Donafenib
DRUG: S1

Sponsor

Fudan University